Biocon Biologics appoints Shreehas Tambe

Shreehas Tambe, Deputy CEO of Biocon Biologics, has been named the new Managing Director and CEO of the company, effective December 5, 2022, according to Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd. According to the firm, Tambe will guide BBL in achieving its objective of dominating the worldwide biosimilars market.

Arun Chandavarkar, who continues to hold the position of non-Executive, non-Independent Director on the Board of Biocon Biologics, has been replaced by Tambe. Tambe has supported Arun Chandavarkar since March 2021 in a significant and highly effective way.

Biocon & Biocon Biologics’ executive chairperson, Kiran Mazumdar-Shaw, said: “The fact that Shreehas is assuming the role of MD & CEO of Biocon Biologics at a time when the business is preparing to assume global leadership in biosimilars with the completion of the Viatris acquisition is very pleasing. A highly skilled executive leadership team will support Shreehas in creating a future-ready, global biosimilars leader and a well-known brand that is dedicated to influencing global healthcare, she continued.”

The Board of Biocon Biologics’ confidence in Tambe to lead the company, he said, “humbles and honours me deeply.”

He talked about how Biocon’s journey has been changed by the recent acquisition of Viatris’ global biosimilars business. These are undoubtedly exciting times, and Tambe said, “I am looking forward to leading Biocon Biologics in the next phase of growth along with an exceptional team.”

Shreehas Tambe

Mazumdar-Shaw thanked Arun for Chandavarkar’s enormous contributions to the Biocon Group and Biocon Biologics over the previous 30 years.

She claimed that under his direction, Biocon Biologics had advanced quickly in achieving its strategic objective of being a world leader in biosimilars. “He oversaw the Company’s recovery from difficulties brought on by the epidemic and redirected the business back toward sustainable growth. I anticipate his full participation on the BBL Board “She stated

It has been Arun Chandavarkar’s “pleasure to have led Biocon Ltd and now, Biocon Biologics through numerous key moments and pioneering achievements over the three-decade tenure with the company,” according to the departing MD of Biocon Biologics.

Tambe has studied pharmaceutical sciences & technology at the University of Pune and possesses a master’s degree in bioprocess technology from ICT (UDCT), University of Mumbai. He received the prestigious Distinguished Alumnus award.